Short Interest in NewAmsterdam Pharma (NASDAQ:NAMS) Drops By 44.0%

NewAmsterdam Pharma (NASDAQ:NAMSGet Free Report) saw a large drop in short interest in the month of January. As of January 31st, there was short interest totalling 272,500 shares, a drop of 44.0% from the January 15th total of 486,200 shares. Approximately 0.8% of the company’s shares are short sold. Based on an average daily trading volume, of 153,500 shares, the short-interest ratio is presently 1.8 days.

NewAmsterdam Pharma Price Performance

NASDAQ:NAMS traded up $0.32 during mid-day trading on Monday, hitting $20.77. The company’s stock had a trading volume of 161,785 shares, compared to its average volume of 236,317. NewAmsterdam Pharma has a 1 year low of $5.63 and a 1 year high of $26.35. The business’s fifty day moving average is $15.19 and its two-hundred day moving average is $11.54.

Analyst Ratings Changes

Several brokerages have recently weighed in on NAMS. Guggenheim began coverage on shares of NewAmsterdam Pharma in a research report on Thursday, January 18th. They issued a “buy” rating and a $30.00 price target for the company. Piper Sandler assumed coverage on NewAmsterdam Pharma in a research note on Tuesday, January 16th. They set an “overweight” rating and a $37.00 price target on the stock. Royal Bank of Canada assumed coverage on NewAmsterdam Pharma in a research note on Monday, October 30th. They set an “outperform” rating and a $25.00 price target on the stock. Finally, William Blair restated an “outperform” rating on shares of NewAmsterdam Pharma in a research note on Wednesday, November 22nd. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, NewAmsterdam Pharma presently has an average rating of “Buy” and a consensus target price of $28.50.

View Our Latest Stock Analysis on NewAmsterdam Pharma

Institutional Investors Weigh In On NewAmsterdam Pharma

Several hedge funds have recently added to or reduced their stakes in NAMS. Wolverine Asset Management LLC boosted its position in NewAmsterdam Pharma by 197.2% in the 4th quarter. Wolverine Asset Management LLC now owns 8,694 shares of the company’s stock worth $97,000 after purchasing an additional 5,769 shares in the last quarter. Affinity Asset Advisors LLC boosted its stake in shares of NewAmsterdam Pharma by 25.0% during the 3rd quarter. Affinity Asset Advisors LLC now owns 125,000 shares of the company’s stock worth $1,156,000 after acquiring an additional 25,000 shares in the last quarter. Schonfeld Strategic Advisors LLC boosted its stake in shares of NewAmsterdam Pharma by 12.9% during the 3rd quarter. Schonfeld Strategic Advisors LLC now owns 64,700 shares of the company’s stock worth $598,000 after acquiring an additional 7,400 shares in the last quarter. RA Capital Management L.P. boosted its stake in shares of NewAmsterdam Pharma by 125.0% during the 2nd quarter. RA Capital Management L.P. now owns 9,000,000 shares of the company’s stock worth $107,010,000 after acquiring an additional 5,000,000 shares in the last quarter. Finally, Bain Capital Life Sciences Investors LLC boosted its stake in shares of NewAmsterdam Pharma by 26.2% during the 2nd quarter. Bain Capital Life Sciences Investors LLC now owns 10,473,913 shares of the company’s stock worth $124,535,000 after acquiring an additional 2,173,913 shares in the last quarter. 96.46% of the stock is owned by hedge funds and other institutional investors.

NewAmsterdam Pharma Company Profile

(Get Free Report)

NewAmsterdam Pharma Company N.V., a clinical-stage biopharmaceutical company, develops oral and non-statin medicines for patients at high risk of cardiovascular disease. Its lead product candidate is obicetrapib, a next generation, oral, and low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in four ongoing Phase 3 and Phase 2b clinical trials as both a monotherapy and a combination therapy with ezetimibe for lowering LDL-C and preventing major adverse cardiovascular events (MACE).

Featured Articles

Receive News & Ratings for NewAmsterdam Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewAmsterdam Pharma and related companies with MarketBeat.com's FREE daily email newsletter.